arXiv:2603.13431v3 Announce Type: replace Abstract: Computational antibody design has seen rapid methodological progress, with dozens of deep generative methods proposed in the past three years, yet the field lacks a standardized benchmark for fair comparison and model development. These methods are evaluated on different SAbDab snapshots, non-overlapping test sets, and incompatible metrics, and the literature fragments the design problem into numerous sub-tasks with no common definition. We introduce CHIMERA-Bench: (CDR Modeling with Epitope-guided Redesign), a unified benchmark built around
The proliferation of deep generative methods for antibody design in recent years necessitates a standardized benchmark to foster methodological progress and fair comparison.
A unified benchmark like CHIMERA-Bench will accelerate the development of more effective and targeted antibody therapies, impacting pharmaceutical innovation and healthcare outcomes.
The fragmented landscape of antibody design evaluation will be replaced by a common framework, allowing for clearer progress tracking and identification of superior computational approaches.
- · deep generative AI researchers
- · pharmaceutical companies
- · biotechnology industry
- · patients with unmet therapeutic needs
- · research groups relying on isolated evaluation metrics
Faster and more efficient discovery of novel therapeutic antibodies.
Reduced R&D costs and shortened timelines for drug development in immunology and oncology.
The emergence of entirely new classes of programmable biologic medicines with unprecedented precision.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG